Validating bifidobacterial species and subspecies identity in commercial probiotic products
- PMID: 26571226
- PMCID: PMC4916961
- DOI: 10.1038/pr.2015.244
Validating bifidobacterial species and subspecies identity in commercial probiotic products
Abstract
Background: The ingestion of probiotics to attempt to improve health is increasingly common; however, quality control of some commercial products can be limited. Clinical practice is shifting toward the routine use of probiotics to aid in prevention of necrotizing enterocolitis in premature infants, and probiotic administration to term infants is increasingly common to treat colic and/or prevent atopic disease. Since bifidobacteria dominate the feces of healthy breast-fed infants, they are often included in infant-targeted probiotics.
Methods: We evaluated 16 probiotic products to determine how well their label claims describe the species of detectable bifidobacteria in the product. Recently developed DNA-based methods were used as a primary means of identification, and were confirmed using culture-based techniques.
Results: We found that the contents of many bifidobacterial probiotic products differ from the ingredient list, sometimes at a subspecies level. Only 1 of the 16 probiotics perfectly matched its bifidobacterial label claims in all samples tested, and both pill-to-pill and lot-to-lot variation were observed.
Conclusion: Given the known differences between various bifidobacterial species and subspecies in metabolic capacity and colonization abilities, the prevalence of misidentified bifidobacteria in these products is cause for concern for those involved in clinical trials and consumers of probiotic products.
Conflict of interest statement
DAM is a co-founder and SAF an employee of Evolve Biosystems, a company focused on diet-based manipulation of the gut microbiota.
Figures
Similar articles
-
Bifidobacterium longum bacteremia in preterm infants receiving probiotics.Clin Infect Dis. 2015 Mar 15;60(6):924-7. doi: 10.1093/cid/ciu946. Epub 2014 Dec 3. Clin Infect Dis. 2015. PMID: 25472946
-
Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis.J Pediatr Gastroenterol Nutr. 2008 May;46(5):608-11. doi: 10.1097/MPG.0b013e3181660694. J Pediatr Gastroenterol Nutr. 2008. PMID: 18493222
-
Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial.PLoS One. 2014 Mar 3;9(3):e89511. doi: 10.1371/journal.pone.0089511. eCollection 2014. PLoS One. 2014. PMID: 24594833 Free PMC article. Clinical Trial.
-
Probiotics for prevention of necrotizing enterocolitis in preterm infants.Evid Based Child Health. 2014 Sep;9(3):584-671. doi: 10.1002/ebch.1976. Evid Based Child Health. 2014. PMID: 25236307 Review.
-
What is the power of evidence recommending routine probiotics for necrotizing enterocolitis prevention in preterm infants?Curr Opin Clin Nutr Metab Care. 2011 May;14(3):302-6. doi: 10.1097/MCO.0b013e3283454e78. Curr Opin Clin Nutr Metab Care. 2011. PMID: 21502919 Review.
Cited by
-
Recent Advances in Necrotizing Enterocolitis Research: Strategies for Implementation in Clinical Practice.Clin Perinatol. 2020 Jun;47(2):383-397. doi: 10.1016/j.clp.2020.02.011. Epub 2020 Mar 4. Clin Perinatol. 2020. PMID: 32439118 Free PMC article. Review.
-
Probiotics to improve the gut microbiome in premature infants: are we there yet?Gut Microbes. 2023 Jan-Dec;15(1):2201160. doi: 10.1080/19490976.2023.2201160. Gut Microbes. 2023. PMID: 37122152 Free PMC article. Review.
-
Comparative Genome Analysis of Bifidobacterium longum subsp. infantis Strains Reveals Variation in Human Milk Oligosaccharide Utilization Genes among Commercial Probiotics.Nutrients. 2020 Oct 23;12(11):3247. doi: 10.3390/nu12113247. Nutrients. 2020. PMID: 33114073 Free PMC article.
-
Development of Real-Time PCR Assay to Specifically Detect 22 Bifidobacterium Species and Subspecies Using Comparative Genomics.Front Microbiol. 2020 Aug 28;11:2087. doi: 10.3389/fmicb.2020.02087. eCollection 2020. Front Microbiol. 2020. PMID: 33013760 Free PMC article.
-
The power of DNA based methods in probiotic authentication.Front Microbiol. 2023 Apr 17;14:1158440. doi: 10.3389/fmicb.2023.1158440. eCollection 2023. Front Microbiol. 2023. PMID: 37138639 Free PMC article.
References
-
- Fasoli S, Marzotto M, Rizzotti L, Rossi F, Dellaglio F, Torriani S. Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysis. Int J Food Microbiol. 2003;82:59–70. - PubMed
-
- Canganella F, Paganini S, Ovidi M, et al. A microbiological investigation on probiotic pharmaceutical products used for human health. Microbiol Res. 1997;152:171–179. - PubMed
-
- Angelakis E, Million M, Henry M, Raoult D. Rapid and Accurate Bacterial Identification in Probiotics and Yoghurts by MALDI-TOF Mass Spectrometry. J Food Sci. 2011;76:568–572. - PubMed
-
- Goldstein EJC, Citron DM, Claros MC, Tyrrell KL. Bacterial counts from five over-the-counter probiotics: Are you getting what you paid for? Anaerobe [Internet] 2014;25:1–4. Available from: http://dx.doi.org/10.1016/j.anaerobe.2013.10.005. - DOI - PubMed
-
- Marcobal A, Underwood MA, Mills Da. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr [Internet] 2008;46:608–611. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18493222. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources